CBG & Derivatives Show Promise for Inflammation & Obesity

This study was published in July 2021 in the journal, Molecules. It examined the effects of several different derivatives of CBG and their effects on inflammation & obesity.

Natural, plant-derived CBG was modified in an attempt to improve its bioavailability and effectiveness. They created 3 new, modified "CBG" molecules, and called them HUM-223, HUM-234, & HUM-233.

For inflammation, the 3 modified CBG molecule treatments "were not significantly better than CBG in these assays". Like CBG, they DID show anti-inflammatory properties; just not better than plain old CBG.

For weight control, the researchers said this: "It is of great interest that while the anti-inflammatory and pain-relieving activity of CBG and HUM-234 are similar, HUM-234 ameliorates weight gain, in contrast to CBG, suggesting this compound has the potential for development as an anti-obesity drug." So by modifying CBG to HUM-234, it shows possible anti-obesity properties that plain old CBG does not.

The study also showed an inverse dose-response effect for the new compounds, similar to that observed in single-molecule CBD. This is important and means effectiveness of single-molecule treatments have a "sweet spot" dose, and exceeding that dose will usually reduce its effectiveness.

HUM-223 was able to significantly reduce swelling in all doses and exceed CBG’s effect at a dose of 10 mg/kg. In addition, it showed activity in reducing pain responses and reducing TNF-α levels. The latter effects were comparable to CBG.

The full-text paper from the journal Molecules is here.